I[NTRODUCTION]{.smallcaps} {#sec1-1}
==========================

It is well known that myocardial hypertrophy is often accompanied by cardiac energy metabolism disorders and that myocardial metabolic disorders aggravate the pathological progression of cardiac hypertrophy to heart failure. Energy metabolism includes mitochondrial metabolism, carbohydrate metabolism, and lipid metabolism. Mitochondria are essential and critical regulators of oxidative phosphorylation.\[[@ref1][@ref2][@ref3]\] Peroxisome proliferator-activated receptor gamma coactivator-1α (PGC-1α), a transcription coactivator of nuclear receptors and master regulator of metabolism, plays an important role in cardiac metabolism regulation. Previous study\[[@ref4]\] had demonstrated that PGC-1α played an important role in the development of pathological cardiac hypertrophy, metabolic disorders, and reactivation of the fetal genetic program on animals models of chronic heart failure. PGC1-α was also involved in mitochondrial biogenesis, which was vital for cell survival. Experimental evidence\[[@ref5]\] supported the roles of mitochondrial dysfunction and oxidative stress as determinants of neuronal death as well as endogenous protective mechanisms after stroke. Accumulating evidence suggested that activation of 5'AMP-activated protein kinase (AMPK) during myocardial ischemia increased both glucose uptake and glycolysis as well as fatty acid oxidation (FAO) during reperfusion. Gain-of-function mutations of AMPK in cardiac muscle might also be causally related to the development of hypertrophic cardiomyopathies.\[[@ref6]\] Mitochondrial FAO is an important energy provider for cardiac work, and changes in cardiac substrate preference are associated with different heart diseases. Carnitine palmitoyltransferase-1 (CPT-1) is thought to be the rate-limiting enzyme in FAO and is inhibited by malonyl-CoA.\[[@ref7]\] Insulin-regulated glucose transporter-4 (GLUT-4) is immunolocalized in rat cardiac muscle under conditions of basal and stimulates glucose uptake, which are achieved by fasting and a combined exercise/insulin stimulus, respectively.\[[@ref8]\] Mitochondrial dysfunction has been demonstrated to contribute to heart disease and its clinical manifestations, and damaged mitochondrial homeostasis might lead to heart failure over time.\[[@ref9]\] Consequently, exploration of a new therapeutic strategy to improve mitochondrial function and energy metabolism may have great clinical significance.

The Shensong Yangxin Capsule (SSYX) was designed and carefully formulated in accordance with the rules of traditional Chinese medicine (TCM) and includes *Panax ginseng, Salvia miltiorrhiza, Nardostachys jatamansi*, and so on.\[[@ref10]\] According to TCMs, SSYX has long been used in China as a traditional Chinese remedy to treat a variety of cardiac diseases, especially to treat cardiac arrhythmias and various arrhythmias in coronary heart disease and chronic heart failure,\[[@ref6][@ref11][@ref12][@ref13]\] angina in coronary heart disease,\[[@ref14][@ref15]\] cardiac remodeling, cardiac fibrosis, regulation of lipid levels, and so on. The above studies have revealed the positive role of SSYX in cardiac energy metabolism, providing the experimental basis for our research. SSYX might block multiple ion channels,\[[@ref16]\] which might change the action potential duration and contribute to its antiarrhythmic effects.\[[@ref17][@ref18]\] SSYX suppressed transforming growth factor-β1/Smad signaling to inhibit fibrosis in diabetic cardiomyopathy and improved cardiac function.\[[@ref19]\] SSYX could block the Smad signaling pathway to attenuate cardiac remodeling after myocardial infarction.\[[@ref11]\] However, the influence of SSYX on myocardium energy metabolism remains unclear. In this study, we studied the regulatory effects of different SSYX drug concentrations on myocardial energy metabolism during AngII-induced cardiac hypertrophy using neonatal rat cardiomyocytes (NRCMs). We particularly focused on the mitochondrial density, glucose metabolism, fatty acid metabolism, and deciphering the underlying molecular mechanisms. Our results might provide a significant therapeutic strategy for ameliorating mitochondrial function through the use of SSYX.

M[ETHODS]{.smallcaps} {#sec1-2}
=====================

Cell culture and treatment {#sec2-1}
--------------------------

All experiments involving animals were conducted in accordance with the 8^th^ Edition of the Guide for the Care and Use of Laboratory Animals (Guide NRC, 2011) published by the US National Institutes of Health and were approved by the Animal Care and Use Committee of Renmin Hospital at Wuhan University (Production license: SCXK 2015--0018). All animals used in this study were postnatal days 1--3 Sprague-Dawley (SD) rats, which were supplied by the Experiment Animal Centre of Wuhan University. We also followed the methods reported in the literature;\[[@ref20]\] NRCMs were isolated from the hearts of SD rat pups on postnatal days 1--3 and were cultured to \<98% purity.\[[@ref21]\] Briefly, SD rats were sacrificed by swift decapitation, and the hearts were excised and minced immediately. Heart tissues were digested in a solution containing 0.08% collagenase Type II and 0.125% trypsin, and the supernatant was collected. The process was repeated 7--10 times. Then, cardiomyocytes were enriched via differential attachment, plated, and cultured in a culture dish with DMEM/F~12~ medium (Gibco, Grand Island, NY, USA) containing 15% fetal bovine serum (Gibco, Grand Island, NY, USA), 1% penicillin/streptomycin, and 0.1 mmol/L BrdU (Sigma-Aldrich, St. Louis, MO, USA).\[[@ref22][@ref23]\] After culturing for 48 h, the culture medium was replaced with complete medium for 12 h. Then, cardiomyocytes were randomly assigned into five groups and subsequently subjected to different treatments. These groups were as follows: control, 10^−6^ mol/L angiotensin (Ang) II (Sigma-Aldrich, St. Louis, MO, USA), 10^−6^ mol/L AngII + SSYX (0.25 μg/ml), 10^−6^ mol/L AngII + SSYX (0.5 μg/ml), and 10^−6^ mol/L AngII + SSYX (1.0 μg/ml). SSYX, provided by Shijiazhuang Yiling Pharmaceutical Co., Ltd. (Shijiazhuang, Hebei, China), was diluted in culture media to various concentrations (0.25, 0.5, and 1.0 μg/ml).

Real-time polymerase chain reaction {#sec2-2}
-----------------------------------

Real-time polymerase chain reaction (PCR) was performed on a StepOne TM Real-Time PCR Instrument (Life technologies, ShangHai, China). Each sample was used for 3 replicates using a SYBR^®^ Premix Ex Taq™ Kit (TaKaRa). The primers were prepared by Wuhan Jin Kairui Bioengineering Co., Ltd. For synthesis, the following primers were used: *β-actin* forward: 5'-CACGATGGAGGGGCCGGACTCATC-3'; reverse: 5'-TAAAGACCTCTATGCCAACACAGT-3'; the gene information of the other factors is shown in \[[Table 1](#T1){ref-type="table"}\].

###### 

Gene information for some factors

  Gene         Species   Forward                             Reverse
  ------------ --------- ----------------------------------- -------------------------------------
  *BNP*        Rat       5'- AGCCAGTCTCCAGAACAATCC -3'       5'- CGGTCTATCTTCTGCCCAAA -3'
  *Capase-3*   Rat       5'- TGGAATGTCAGCTCGCAATG -3'        5'- CAGGTCCGTTCGTTCCAAAA -3'
  *PGC-1α*     Rat       5'-GGAGCAATAAAGCAAAGCGCA-3'         5'- GTGTGAGGAGGGTCATCGTT-3'
  *AMPK*       Rat       5'-ACA GAA GCC AAA TCA GGG ACT-3'   5'-CAC GGA TGA GGT AAG AGA GAC T-3'
  *CPT-1*      Rat       5'-CCA GGC AAA GAG ACA GAC TTG-3'   5'-GCCAAACCTTGAAGAAGCGA-3'
  *GLUT-4*     Rat       5'-GTATGTTGCGGATGCTATGG -3'         5'-CCTCTGGTTTCAGGCACTCT -3'

*BNP*: Brain natriuretic peptide; *Capase-3*: Cysteiny aspartate specific proteinase-3; *PGC-1α*: Peroxisome proliferator-activated receptor coactivator 1 alpha; *AMPK*: AMP-activated protein kinase; *CPT-1*: Carnitine acyltransferase enzyme-1; *GLUT-4*: Glucose transporter protein-4.

Western blotting analysis {#sec2-3}
-------------------------

TBS buffer solution was used to moisten the adherent cells 2--3 times, and the last time, the residual liquid was removed. A suitable volume of total protein extraction reagent (with proteinase inhibitor added for a few minutes) was added for 3--5 min to the culture plate/bottle. The plate/bottle was shaken repeatedly during this period to ensure that the reagent fully contacted the cells. The cells and reagents were scraped with cell scrapers and then collected in 1.5 ml centrifuge tubes. The sample was placed on an ice bath 30 min, and a pipette was used repeatedly to ensure that the cells were completely lysed. Centrifuged for 5 minutes at 4°C and 13000×g with the following primary antibodies: AMPKα1 (1:200 dilution, sc-130394, Santa Cruz Biotechnology), p-*AMPK* (1:1000 dilution, YT639-FIW, Baiao Bolai, BeiJing), *PGC-1α* (1:500 dilution, sc-518025, Santa Cruz Biotechnology), *CPT-1* (1:200 dilution, sc-514555, Santa Cruz Biotechnology), and *GLUT-4* (1:1000 dilution, sc-53566, Santa Cruz Biotechnology). The supernatant was collected and was considered the total protein solution. A BCA protein (Beyotime, Nanjing, China) concentration assay kit was used to determine the concentration of the sample protein. The protein concentration was also determined by SDS-PAGE electrophoresis. The film was scanned and archived, and the AlphaEaseFC software (Alpha Innotech, California, USA) processing system was used to analyze the optical density of the target band.

Alpha-actinin staining detects myocardial cell size {#sec2-4}
---------------------------------------------------

The NRCM cell suspension was added to a cover glass and cultured in an incubator with a CO~2~ concentration of 5% at 37°C for 2 h. Then, 2 ml of the cell culture solution was added and incubated for approximately 6 h. Cells were then fixed with 4% polyoxymethylene for 30 min. To prevent the flow of antibodies, the creeping piece was dried slightly, and then, a uniform position in the middle cell of the cover glass was drawn with a histochemical pen, adding 50--100 μl of working fluid to break the membrane, followed by incubation for 10 min at room temperature. A 3% hydrogen peroxide solution was added to the ring and was incubated for 20 min at room temperature. The glass was washed with PBS (pH 7.4) 3 times and placed on a shaking table. After drying, the cells were covered with 5% bovine serum albumin (BSA). The cells were laid in a wet box at 4°C overnight. The glass was washed in PBS (pH 7.4) 3 times on a shaking table and washed for 5 min each time. After dripping, the glass was incubated for 50 min at room temperature with two anti-covering cells from a kit. Each slice was placed in 50--100 μl of DAPI dye and incubated at room temperature for 5 min. A proper amount of anti-fluorescence quenching agent was added to the cells, and the cover glass slide was sealed and observed under a fluorescence microscope.

MitoTracker staining and confocal microscopy {#sec2-5}
--------------------------------------------

NRCMs were plated in chamber slides (BD Bioscience, Sparks, MD, USA) at a density of 1 × 10^6^ cells/well and treated with or without SSYX for 48 h. Cells were then stained with MitoTracker^®^ Red CMXRos (Yisheng Biological Technology, Shanghai, China) at a concentration of 300 nmol/L diluted in prewarmed culture media for 30 min. MitoTracker^®^ Red CMXRos contains a weak thiol-reactive chloromethyl functional group labeled with mitochondria that can label mitochondria in cardiomyocytes and is used to observe the number of mitochondria in cells. Then, cells were fixed in 4% formaldehyde in prewarmed culture media and stained with DAPI staining solution (Beyotime, China) to mark cell nuclei. A total of 20 fields/well (×400) were taken by a confocal microscope (Carl Zeiss, Thuringia, Germany). MitoTracker^®^ Red CMXRos make mitochondria to emit a red fluorescence under a confocal microscope. Therefore, we were able to judge the number and density of mitochondria based on the amount of red fluorescence. The cell size and fluorescence intensity were measured by ImageJ (National Institutes of Health, NIH, USA) and Zeiss software (Carl Zeiss Jena, Germany), respectively.

Statistical analysis {#sec2-6}
--------------------

Statistical analyses and all calculations were performed using GraphPad Prism version 5.0 statistical software (GraphPad Software, San Diego, CA, USA). All experimental data were expressed as the mean ± standard deviation. One-way analysis of variance (ANOVA; three or more groups) was used for intergroup comparison. A value of *P* \< 0.05 was considered statistically significant.

R[ESULTS]{.smallcaps} {#sec1-3}
=====================

Shensong Yangxin Capsule attenuates the myocardial hypertrophy and myocardial apoptosis induced by Angiotensin II *in vivo* {#sec2-7}
---------------------------------------------------------------------------------------------------------------------------

To evaluate the effect of the SSYX on the myocardial hypertrophy and apoptosis induced by AngII *in vivo*, NRCMs were cultured for 48 h, 10^−6^ mol/L AngII was added to the experimental group for 24 h, and α-actinin staining was used to observe myocardial hypertrophy in each group \[Figure [1a](#F1){ref-type="fig"} and [1b](#F1){ref-type="fig"}\]. PCR was used to detect the mRNA expression of the cardiomyocyte hypertrophy marker -- brain natriuretic peptide (*BNP*) \[[Figure 1c](#F1){ref-type="fig"}\] and cardiomyocyte apoptosis factor marker -- *Capase-3* \[[Figure 1d](#F1){ref-type="fig"}\]. Comparing with the control group, cell volume in AngII group (28,369 ± 1783 μm^2^ vs. 222,400 ± 12,602 μm^2^, *t* = 24.380, *P* \< 0.0001, *n* = 5) increased. Comparing with the control group, the expression of *BNP* and *Capase-3* mRNA in AngII group (0.8654 ± 0.0542 vs. 1.2060 ± 0.0206, *t* = 10.730, *P* \< 0.0001; 0.5400 ± 0.0758 vs. 1.1170 ± 0.0160, *t* = 11.740, *P* \< 0.0001, *n* = 5 per dosage group) increased. The cardiac hypertrophy model was successfully constructed. Then, the cells were treated with 0.25, 0.5, and 1.0 μg/ml SSYX for 12 h. Comparing with the AngII group, cell volume in 0.25 μg/ml SSYX (222,400 ± 12,602 μm^2^ vs. 190,000 ± 15,811 μm^2^, *t* = 4.070, *P* = 0.0024, *n* = 5), 0.5 μg/ml SSYX (222,400 ± 12,602 μm^2^ vs. 100,000 ± 15,811 μm^2^, *t* = 15.380, *P* \< 0.0001, *n* = 5), and 1.0 μg/ml SSYX (22,2400 ± 12,602 μm^2^ vs. 64,000 ± 11,402 μm^2^, *t* = 19.900, *P* \< 0.0001, *n* = 5) groups decreased. Comparing with the AngII group, the expression of *BNP* and *Capase-3* mRNA in 0.25 μg/ml SSYX (1.2060 ± 0.0206 vs. 1.0770 ± 0.0581, *t* = 4.072, *P* = 0.0024; 1.1170 ± 0.0160 vs. 1.0880 ± 0.0739, *t* = 0.5942, *P* \> 0.9999; *n* = 5, respectively), 0.5 μg/ml SSYX (1.2060 ± 0.0206 vs. 0.7814 ± 0.0684, *t* = 13.370, *P* \< 0.0001; 1.1170 ± 0.0160 vs. 0.8724 ± 0.1181, *t* = 4.977, *P* = 0.0007; *n* = 5, respectively), and 1.0 μg/ml SSYX (1.2060 ± 0.0206 vs. 0.5992 ± 0.0348, *t* = 19.110, *P* \< 0.0001; 1.1170 ± 0.0160 vs. 0.8364 ± 0.0692, *t* = 5.710, *P* = 0.0001; *n* = 5, respectively) decreased. Studies have shown that only when the concentration of SSYX drug reached 0.5 μg/ml could reduce the expression of *Capase-3* mRNA and resist the apoptosis of cardiomyocytes induced by AngII. However, low concentrations of SSYX (0.25 μg/ml) have been able to reduce the expression of *BNP* mRNA and alleviate AngII-induced cardiomyocyte hypertrophy, and its effect was positively related to the drug concentration.

![Myocardial hypertrophy and apoptosis in the control, AngII, SSYX (0.25, 0.5, and 1.0 μg/ml drug concentration) groups. (a) Representative immunofluorescent (α-actinin) images of NRCMs in each group. Bar = 200 μm. Red staining denotes α-actinin-stained cardiomyocytes. Blue staining denotes DAPI-stained myocardial cell nuclei. (b) Summarized data of surface area of myocardial cells in each group. (c) Relative expression levels of *BNP* mRNA in each group. (d) Relative expression levels of *Capase-3* mRNA in each group. \**P* \< 0.0001 versus the control group; ^†^*P* \< 0.05 versus the AngII group. The data are expressed as the mean ± SD (*n* = 5, samples were collected from five different passages). The symbols "\*, ^†^" indicate that the value of cell volume and *BNP* and *Capase-3* mRNA expression significantly differed from different groups. *BNP*: Brain natriuretic peptide; *Capase-3*: Cysteiny aspartate specific proteinase-3; mRNA: Messenger RNA; Ang: Angiotensin; SSYX: Shensong Yangxin Capsule; NRCMs: Neonatal rat cardiomyocytes; SD: Standard deviation.](CMJ-131-2287-g001){#F1}

Shensong Yangxin Capsule protects the mitochondrial density in the process of Angiotensin II-induced cardiac hypertrophy {#sec2-8}
------------------------------------------------------------------------------------------------------------------------

To evaluate the protective effect of SSYX on mitochondria, AngII-induced cells were treated with SSYX at different concentrations of 0.25, 0.5, and 1.0 μg/ml for 12 h. Then, 300 μmol/L preheated mitochondrial MitoTracker Red (40741ES50, Yisheng Biological Technology Co., Ltd. Shanghai) was added to the cell plates for 30 min, and the cells were observed with a confocal microscope \[[Figure 2a](#F2){ref-type="fig"}\]. We found that the number of mitochondria decreased after adding 10^−6^ mol/L AngII compared with the control group (21.3700 ± 0.7222 vs. 18.3300 ± 0.8895, *t* = 5.045, *P* = 0.0002, *n* = 5; Normalized MitoTracker Red content, [Figure 2b](#F2){ref-type="fig"}). However, when different concentrations of SSYX were added to AngII-induced cells, the number of mitochondria in cardiomyocytes began to increase. When the different concentrations (0.25 μg/ml, 0.5 μg/ml, and 1.0 μg/ml) of SSYX were compared, it was interesting to note that the number of mitochondria increased with increasing concentrations of SSYX (0.25 μg/ml,18.3300 ± 0.8895 vs. 24.4900 ± 0.9041, *t* = 10.240, *P* \< 0.0001;0.5 μg/ml,18.3300 ± 0.8895 vs. 25.9800 ± 0.8187, *t* = 12.710, *P* \< 0.0001; and 1.0 μg/ml,18.3300 ± 0.8895 vs. 24.2900 ± 1.3120, *t* = 9.902, *P* \< 0.0001; *n* = 5 per dosage group). Therefore, we concluded that SSYX had a protective effect on the mitochondrial density in AngII-induced cardiac hypertrophy. This effect became more obvious as the concentration of SSYX increased.

![Mitochondrial density in AngII-induced cardiomyocyte hypertrophy 12 h after SSYX treatment with different drug concentrations. (a) Representative fluorescence microscope image of cardiomyocytes costained with mitochondrial Mito-Red Tracker and myocardial cell nuclei DAPI staining at 12 h after treatment with 0.25, 0.5, and 1.0 μg/ml SSYX. Scale bars = 50 μm. Red staining denotes Mito-Red Tracker-stained mitochondria. Blue staining denotes DAPI-stained myocardial cell nuclei. (b) Normalized MitoTracker Red content. \**P* = 0.0002 versus control group; ^†^*P* \< 0.0001 versus AngII group. The data were expressed as the mean ± SD (*n* = 5, samples were collected from five different passages), the symbols "\*, ^†^" indicate that the value of Mito-Red Tracker content significantly differed from different groups. Ang: Angiotensin; SSYX: Shensong Yangxin Capsule; SD: Standard deviation.](CMJ-131-2287-g002){#F2}

Shensong Yangxin Capsule regulates mitochondrial biogenesis and energy balance with peroxisome proliferator-activated receptor gamma coactivator-1 alpha and AMP-activated protein kinase activation {#sec2-9}
----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

To explore the effects of SSYX on mitochondrial biogenesis and energy balance, we examined the mRNA and protein expression of the mitochondrial biological origin and energy balance key factors -- *PGC-1α* and *AMPK* -- after treating cells with the above concentrations of SSYX (0.25 μg/ml, 0.5 μg/ml, and 1.0 μg/ml) \[Figure [3a](#F3){ref-type="fig"}--[3d](#F3){ref-type="fig"}\]. *PGC-1α* and *AMPK* mRNA were detected by PCR. PGC-1α, p-AMPK, and *AMPK* protein expressions were detected by Western blotting analysis. As shown in [Figure 3c](#F3){ref-type="fig"}, the expression of AMPK mRNA decreased in AngII group compared with the control group (1.1940 ± 0.0447 vs. 0.8872 ± 0.0779, *t* = 8.450, *P* \< 0.0001, *n* = 5), while it increased in 0.25 μg/ml SSYX (0.8872 ± 0.0779 vs. 1.1500 ± 0.0507, *t* = 7.239, *P* \< 0.0001, *n* = 5), 0.5 μg/ml SSYX (0.8872 ± 0.0779 vs. 1.2280 ± 0.0623, *t* = 9.379, *P* \< 0.0001, *n* = 5), and 1.0 μg/ml SSYX (0.8872 ± 0.0779 vs. 1.3020 ± 0.0450, *t* = 11.400, *P* \< 0.0001, *n* = 5) groups compared with AngII group. The expression of *PGC-1α* mRNA decreased in AngII group compared with the control group (1.3640 ± 0.0545 vs. 0.8892 ± 0.0848, *t* = 9.865, *P* \< 0.0001, *n* = 5), while it increased in 0.25 μg/ml SSYX (0.8892 ± 0.0848 vs. 1.0970 ± 0.0994 *t* = 4.319, *P* = 0.0013, *n* = 5), 0.5 μg/ml SSYX (0.8892 ± 0.0848 vs. 1.2330 ± 0.0564, *t* = 7.150, *P* \< 0.0001, *n* = 5), and 1.0 μg/ml SSYX (0.8892 ± 0.0848 vs. 1.1640 ± 0.0755, *t* = 5.720, *P* \< 0.0001, *n* = 5) groups compared with AngII group. To explore time-depend effect of SSYX on mitochondrial biogenesis and energy balance, 0.5 μg/ml SSYX was added into cells for 0, 6, 12, 24, and 48 h \[Figure [3e](#F3){ref-type="fig"}--[3h](#F3){ref-type="fig"}\]. The expression of *AMPK* and *PGC-1α* mRNA presented an upward trend in different hours (AMPK: 6 h, 14.6100 ± 0.6205 vs. 16.5200 ± 0.7450, *t* = 3.456, *P* = 0.0250; 12 h, 14.6100 ± 0.6205 vs. 18.3200 ± 0.9965, *t* = 6.720, *P* \< 0.0001; 24 h, 14.6100 ± 0.6205 vs. 21.8800 ± 0.8208, *t* = 13.160, *P* \< 0.0001; and 48 h, 14.6100 ± 0.6205 vs. 23.7400 ± 1.097, *t* = 16.530, *P* \< 0.0001; *n* = 5 per dosage group;PGC-1α: 12 h, 11.4700 ± 0.7252 vs 16.9000 ± 1.0150, *t* = 7.910, *P* \< 0.0001; 24 h, 11.4700 ± 0.7252 vs. 20.8800 ± 1.2340, *t* = 13.710, *P* \< 0.0001; and 48 h, 11.4700 ± 0.7252 vs. 22.0300 ± 1.4180, *t* = 15.390, *P* \< 0.0001; *n* = 5 per dosage group). In summary, SSYX increased the mRNA and protein expression of AMPK and *PGC-1α* in a dose-dependent manner. Compared with different hours (from 0 to 48 h), the effect was becoming more and more remarkable. Therefore, SSYX could improve mitochondrial biogenesis and energy balance in cardiac hypertrophy.

![Expression of *PGC-1α* and AMPK mRNAs and protein in AngII-induced cardiac hypertrophy. (a) Expression of p-AMPK and AMPK protein in the control, AngII, and SSYX (0.25, 0.5, and 1.0 μg/ml) groups. (b) Expression of *PGC-1α* protein in each group. (c) Relative expression levels of *AMPK* mRNA in groups. (d) Relative expression levels of *PGC-1α* mRNA in groups. (e) Expression of p-AMPK and AMPK protein treated with 0.5 μg/ml SSYX for 0, 6, 12, 24, and 48 h. (f) Expression of *PGC-1α* protein in groups. (g) Relative expression levels of *AMPK* mRNA in groups; (h) relative expression levels of *PGC-1α* mRNA in groups. \**P* \< 0.0001 versus control group; ^†^*P* \< 0.05 versus AngII group; \**P* \< 0.0001 versus 0 h; the data are expressed as the mean ± SD (*n* = 5, samples were collected from five different passages). The symbols "\*, ^†^" indicate that the value of *PGC-1α* and AMPK mRNA expression significantly differed from those of different groups and different durations. p-AMPK: Activity AMP-activated protein kinase; AMPK: AMP-activated protein kinase; PGC-1α: Peroxisome proliferator-activated receptor coactivator 1 alpha; mRNA: Messenger RNA; Ang: Angiotensin; SD: Standard deviation; SSYX: Shensong Yangxin Capsule.](CMJ-131-2287-g003){#F3}

Shensong Yangxin Capsule regulates fatty acids and glucose oxidation during the process of cardiac hypertrophy {#sec2-10}
--------------------------------------------------------------------------------------------------------------

To explore the effects of SSYX on fatty acids and glucose oxidation, we examined the mRNA and protein expression of the fatty acid and glucose oxidation key factors -- *CPT-1* and *GLUT-4* -- after treating cells with 0.25 μg/ml, 0.5 μg/ml, and 1.0 μg/ml SSYX \[Figure [4a](#F4){ref-type="fig"}--[4d](#F4){ref-type="fig"}\]. *CPT-1* and *GLUT-4* mRNA were detected by PCR. *CPT-1* and *GLUT-4* protein expression were detected by Western blotting analysis. As shown in [Figure 4c](#F4){ref-type="fig"}, adding AngII into cardiomyocytes, the decrease of *CPT-1* mRNA expression was not statistically significant compared with the control group. During the process of AngII-induced cardiac hypertrophy, the increase of *CPT-1* mRNA expression in 0.25 and 0.5 μg/ml SSYX group was not statistically significant compared with AngII group. Studies have shown that lipid metabolism was only affected when the concentration of SSYX reached 1.0 μg/ml (0.7348 ± 0.0594 vs. 0.9880 ± 0.0851, *t* = 4.994, *P* = 0.0007, *n* = 5), 0.25, and 0.5 μg/ml SSYX had less effect on lipid metabolism. Different from fatty acid metabolism, in the process of AngII-induced cardiomyocyte hypertrophy, the expression of *GLUT-4* mRNA was decreased and glucose metabolism was weakened. When 0.25 μg/ml SSYX was used to treat cardiac hypertrophy, the effect on glucose metabolism was small, and the increase of *GLUT-4* mRNA expression was not statistically significant compared with AngII group. Only when the concentration of SSYX reached 0.5 μg/ml, its effect on glucose metabolism would appear. At this time, the expression of *GLUT-4* mRNA in the 0.5 μg/ml SSYX group (1.5640 ± 0.0599 vs. 1.7720 ± 0.0660, *t* = 3.783, *P* = 0.0117, *n* = 5) and 1.0 μg/ml SSYX group (1.5640 ± 0.0599 vs. 2.0490 ± 0.1280, *t* = 8.808, *P* \< 0.0001, *n* = 5) increased. SSYX increased mRNA and protein expression of CPT-1 and GLUT-4 with the increasing drug concentration. To explore time-depend effect of SSYX on fatty acids and glucose oxidation, 0.5 μg/ml SSYX was added into cells for 0, 6, 12, 24, and 48 h \[Figure [4e](#F4){ref-type="fig"}--[4h](#F4){ref-type="fig"}\]. The results showed that the effect of 0.5 μg/ml SSYX on the fatty acid metabolism of cardiomyocytes had no obvious regularity with time, only when the action time reached 24 h, and the expression of CPT-1 mRNA was statistically significant (15.1600 ± 1.0960 vs. 18.5800 ± 0.9049, *t* = 6.048, *P* \< 0.0001, *n* = 5). The effect of 0.5 μg/ml SSYX on the glucose metabolism of cardiomyocytes became more and more significant with time, and the expression of *GLUT-4* mRNA was measured at 0, 6 (10.2100 ± 0.9485 vs. 12.9700 ± 0.8221, *t* = 4.763, *P* = 0.0012, *n* = 5), 12 (10.2100 ± 0.9485 vs. 16.9100 ± 0.8481, *t* = 11.590, *P* \< 0.0001, *n* = 5), 24 (10.2100 ± 0.9485 vs. 19.0900 ± 0.9797, *t* = 15.360, *P* \< 0.0001, *n* = 5), and 48 (10.2100 ± 0.9485 vs. 14.1900 ± 0.9611, *t* = 6.877, *P* \< 0.0001, *n* = 5) h. Compared with different hours (from 0 to 48 h), the effect was becoming more and more remarkable, but when the action time reached 48 h, both *CPT-1* and *GLUT-4* mRNA and protein expression decreased, which suggested that glucose metabolism and fatty acid metabolism were both weakened at this time. In conclusion, SSYX can improve fatty acid metabolism and glucose metabolism in cardiac hypertrophy and it needs to reach the appropriate dose and time.

![Expression of CPT-1 and GLUT-4 mRNAs and protein in AngII-induced cardiac hypertrophy. (a) Expression of CPT-1 protein in the control, AngII, and SSYX (0.25, 0.5, and 1.0 μg/ml) groups. (b) Expression of GLUT-4 protein in each group. (c) Relative expression levels of *CPT-1* mRNA in each group. (d) Relative expression levels of *GLUT-4* mRNA in groups. (e) Expression of CPT-1 protein treated with 0.5 μg/ml SSYX for 0, 6, 12, 24, and 48 h. (f) Expression of GLUT-4 protein in each group. (g) Relative expression levels of *CPT-1* mRNA in each group. (h) Relative expression levels of *GLUT-4* mRNA in each group. \**P* \< 0.0001 versus control group; ^†^*P* \< 0.05 versus AngII group; \**P* \< 0.05 versus 0 h; the data are expressed as the mean ± SD (*n* = 5, samples were collected from five different passages). The symbols "\*, ^†^" indicate that the value of *CPT-1* and *GLUT-4* mRNA expression significantly differed from different groups and durations. CPT-1: Carnitine acyltransferase enzyme-1; GLUT-4: Glucose transporter protein-4; mRNA: Messenger RNA; Ang: Angiotensin; SSYX: Shensong Yangxin Capsule; SD: Standard deviation.](CMJ-131-2287-g004){#F4}

D[ISCUSSION]{.smallcaps} {#sec1-4}
========================

This study revealed that SSYX not only can reduce the cardiomyocyte hypertrophy and apoptosis induced by AngII but also can protect the mitochondrial density in hypertrophic cardiomyocytes in a dose-dependent manner (from 0.25 to 1.0 μg/ml). In addition, SSYX improved energy metabolism by activating the expression of related factors in AngII-induced cardiac hypertrophy, such as mitochondrial biogenesis factor -- *PGC-1α*, energy balance factor -- *AMPK*, fatty acid metabolism factor -- *CPT-1*, and glucose metabolism factor -- *GLUT-4*. Moreover, these effects need appropriate drug action time and drug concentration. We found that only when the concentration of SSYX reached 1.0 μg/ml, lipid metabolism was affected, and 0.25 and 0.5 μg/ml SSYX had less effect on it. Unlike fatty acid metabolism, when the concentration of SSYX reached 0.5 μg/ml, the expression of GLUT-4 mRNA was increased and its effect on glucose metabolism had appeared. SSYX not only increased mRNA and protein expression of *CPT-1* and *GLUT-4*, but the effect increased with the increasing drug concentration. In order to observe the best action time, we chose the same concentration of SSYX (0.5 μg/ml) for different time (from 0 to 48 h); the effect on mitochondrial biogenesis and energy balance was becoming more and more remarkable. However, when the action time reached 48 h, both *CPT-1* and *GLUT-4* mRNA and protein expression decreased, which suggests that glucose and fatty acid metabolism were both weakened at this time. It was gratifying that our findings were not only consistent with our expectations but also consistent with previous experiments.

Mitochondrial biogenesis is regulated by a complex regulatory system. Peroxisome proliferator-activated receptor coactivator 1 alpha (*PGC-1α*) is a critical regulator that participates in mitochondrial biogenesis and oxidative metabolism in the heart.\[[@ref24][@ref25]\] Some reports have shown that the mitochondrial function is increased by the activation of *PGC-1α*.\[[@ref26]\] AMP-activated protein kinase (*AMPK*) is a key modulator of lipid and glucose metabolism and energy balance. When the ATP levels are reduced, *AMPK* is rapidly activated and becomes involved in cell energy regulation.\[[@ref27]\] The current study confirmed that SSYX activated *AMPK* and upregulated the expression of *PGC-1α* compared with the control group. Myocardial remodeling can reduce the oxygen level in myocardial tissue and affects substrate oxidation, thus resulting in a reduction of the oxidative phosphorylation efficiency.\[[@ref2]\] In this experiment, SSYX increased the expression levels of carnitine acyltransferase enzyme-1 (*CPT-1*) and glucose transporter protein-4 (*GLUT-4*) in cardiac hypertrophy, which were key factors of fatty acid and glucose oxidation, respectively. These studies illustrated that SSYX promoted the oxidation of fatty acids and glucose and protected cardiac myocytes from energy deficiency.

However, the experiments still have many limitations. This study did not deeply investigate the specific mechanism SSYX regulated the mitochondria, glucose metabolism, and fatty acid metabolism. We did not conduct animal experiments to verify our results. Although SSYX at different drug concentrations was used in this study, due to the limited number of experimental groups, the optimal concentration of SSYX for regulating myocardial energy metabolism was not explored. In addition, SSYX itself is a compound preparation of TCM, so we did not study which specific component of SSYX regulates energy metabolism. These experiments will be the next stage of our research. We are fully aware that many issues still need to be resolved, but this study is still significant.

We proposed and demonstrated for the first time that SSYX regulated myocardial energy metabolism. SSYX not only reduced AngII-induced cardiac hypertrophy and cardiomyocyte apoptosis but also regulated the myocardial mitochondrial density and energy metabolism in cardiac hypertrophy. The mitochondrion is the main organelle of oxidative phosphorylation. Mitochondrial density is relatively reduced during cardiac hypertrophy, so oxidative phosphorylation of the myocardium produces insufficient energy to meet the needs of hypertrophic cardiomyocytes, which leads to myocardial dysfunction and aggravates myocardial injury. We demonstrated that SSYX increased the myocardial mitochondrial density while cardiac hypertrophy, which implied that SSYX increased the capacity of the oxidative phosphorylation of cells during myocardial hypertrophy, improved myocardial function and slow or even reversed the progression of cardiac hypertrophy to heart failure. These results provided evidence of a new treatment for cardiac hypertrophy and heart failure.

In summary, SSYX can increase myocardial energy metabolism in AngII-induced cardiac hypertrophy. SSYX can be considered to be an alternative therapeutic remedy for myocardial hypertrophy.
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